Cytokinetics, Inc. — 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. This is an annual filing; quarterly figures below are included for context. Cytokinetics is a clinical-stage biopharmaceutical company with no approved products or commercial product sales. Its programs focus on skeletal and cardiac muscle function.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Total revenue | $7.6 million | $4.0 million |
| Research and development expense | $35.6 million | $37.2 million |
| General and administrative expense | $12.4 million | $13.6 million |
| Operating loss | $40.5 million | $48.0 million |
| Net loss | $40.4 million | $47.9 million |
| Net loss per share, basic and diluted | $0.38 | $0.72 |
| Net cash used in operating activities | $33.4 million | $45.6 million |
Revenue was primarily collaboration reimbursements, research grants, and other research revenue—not product sales. The company reported no income tax provision in 2012. Conventional product or gross margins are not meaningful for this development-stage business; the filing does not provide a clear margin measure.
- At year-end, cash and cash equivalents were $14.9 million and short-term investments were $59.1 million, totaling $74.0 million. Working capital was $69.3 million.
- Total liabilities were $7.5 million. Equipment-financing debt was repaid in March 2012; no such debt remained at year-end.
- Cash used in investing activities was $28.8 million, mainly net purchases of investments. Financing activities provided $58.3 million, principally from the June 2012 securities offerings.
- Fourth-quarter 2012 revenue was $2.2 million; net loss was $11.5 million and loss per share was $0.08.
Material changes versus prior period
- Revenue increased by $3.6 million year over year, including higher Amgen reimbursements and revenue from Global Blood and MyoKardia, as well as grant revenue.
- Operating expenses fell by $3.9 million, with lower research and development and administrative costs; the 2011 comparison included $1.2 million of restructuring charges.
- Net loss narrowed by $7.5 million. Operating cash use also declined, although the company continued to incur substantial losses.
- Cash and investments rose from $49.0 million to $74.0 million, principally reflecting the June 2012 financing. The company issued common and convertible preferred shares and warrants for approximately $60.0 million gross proceeds ($56.0 million net). Common shares outstanding increased substantially, and potential dilution from warrants and convertible preferred stock remained significant.
Pipeline, outlook, and principal risks
- Tirasemtiv: A Phase IIb ALS study, BENEFIT-ALS, opened to enrollment in October 2012 and was designed for approximately 400 patients. Management expected enrollment completion by mid-2013 and results by year-end 2013. The company anticipated at least one confirmatory Phase III trial would be needed for potential ALS approval and said additional funding would be required.
- CK-2127107: Its IND cleared FDA review; management expected to begin a Phase I study in healthy volunteers in the first half of 2013.
- Omecamtiv mecarbil: Amgen leads development outside Japan. The Phase IIb ATOMIC-AHF trial was expected to complete enrollment in the first half of 2013, with results anticipated mid-year. COSMIC-HF opened to enrollment in February 2013 to assess oral formulations in heart failure patients.
- 2013 expense outlook: R&D expense was forecast at $43–$47 million and G&A at $14–$15 million; the company expected both to increase from 2012. No clear revenue guidance was provided.
- Management believed existing cash, cash equivalents, investments, and investment income would fund projected operations for at least 12 months, but emphasized that this depended on assumptions. The company expected continuing losses and would need further funding for future development, including tirasemtiv Phase III work. Future financing might dilute shareholders or require giving up rights.
- Clinical outcomes and regulatory approval are uncertain. Tirasemtiv trials reported dizziness and other adverse events; in a claudication study, higher dose and drug concentration were associated with worse six-minute walk performance. Tirasemtiv also increased riluzole levels in a drug-interaction study. High doses of omecamtiv mecarbil were associated with excessive prolongation of systolic ejection time and other dose-limiting effects.
- Key dependencies include Amgen’s decisions and execution, the ability to secure partners or capital, trial enrollment and results, manufacturing supply, regulatory decisions, and intellectual-property protection. The company reported no material legal proceedings. The auditor gave an unqualified opinion and reported effective internal control over financial reporting.
Important facts for investors to verify
- Whether trial timelines and endpoints were achieved, and what the complete clinical efficacy and safety data show—especially for BENEFIT-ALS, ATOMIC-AHF, and COSMIC-HF.
- Cash burn, remaining liquidity, and whether additional financing or partnership proceeds are available to fund later-stage trials.
- Potential dilution from outstanding warrants, convertible preferred stock, options, and any further equity issuance.
- Amgen’s continued commitment to omecamtiv mecarbil and the financial terms, milestones, royalties, and participation rights applicable to the collaboration.
- Whether reported adverse effects, drug interactions, and manufacturing or regulatory issues alter development plans or the candidates’ risk-benefit profiles.